1. Home
  2. BLTE

BLTE

Belite Bio Inc

Logo Belite Bio Inc

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 12:06pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Founded: 2018 Country:
United States
United States
Employees: 20 City: N/A
Market Cap: 1.1B IPO Year: 2022
Target Price: $48.80 AVG Volume (30 days): 57.0K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.19 EPS Growth: N/A
52 Week Low/High: $11.00 - $48.60 Next Earning Date: 05-11-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): -33.33%

Share on Social Networks: